XTLB
Xtl Biopharmaceuticals·NASDAQ
--
--(--)
--
--(--)
0.94 / 10
Underperform
Corporate fundamentals rate weak at 0.9/10. Beneficial factors: Interest coverage ratio (EBIT / Interest expense) (%) and Total operating revenue (YoY growth rate %), balanced by issues in Days sales outstanding. Resultant assessment: challenging.
Analysis Checks(3/4)
Total operating revenue (YoY growth rate %)
Value294.17
Score2/3
Weight-119.73%
1M Return1.11%
Value294.17
Score2/3
Weight-119.73%
1M Return1.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight111.81%
1M Return-1.11%
Value27.58
Score2/3
Weight111.81%
1M Return-1.11%
Days sales outstanding
Value32.90
Score1/3
Weight154.05%
1M Return-1.57%
Value32.90
Score1/3
Weight154.05%
1M Return-1.57%
Operating revenue (YoY growth rate %)
Value392.33
Score2/3
Weight-46.13%
1M Return0.43%
Value392.33
Score2/3
Weight-46.13%
1M Return0.43%
Total operating revenue (YoY growth rate %)
Value294.17
Score2/3
Weight-119.73%
1M Return1.11%
Value294.17
Score2/3
Weight-119.73%
1M Return1.11%
Days sales outstanding
Value32.90
Score1/3
Weight154.05%
1M Return-1.57%
Value32.90
Score1/3
Weight154.05%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight111.81%
1M Return-1.11%
Value27.58
Score2/3
Weight111.81%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value392.33
Score2/3
Weight-46.13%
1M Return0.43%
Value392.33
Score2/3
Weight-46.13%
1M Return0.43%
Is XTLB undervalued or overvalued?
- XTLB scores 0.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -204.16% ROE, -651.65% net margin, -1.61 P/E ratio, -215.42 P/B ratio, and -166.67% earnings growth, these metrics solidify its Underperform investment rating.
